May 4, 2021
For the Children: Advancing the Cause of Pediatric Cancer Research
Why are cancer treatments for children lagging behind the latest advancements in clinical oncology? CrownBio Director Mike Batey takes a closer look at pediatric cancer and how recent regulatory changes and additional research focus may deliver new therapies for kids. Each year approximately 400,000 children from infants to teenagers are diagnosed with ...
LEARN MORE
April 1, 2021
Expanding the Horizon of Antibody-Drug Conjugates for Cancer Treatment
This post explores the fast-expanding topic of antibody-drug conjugates (ADCs), including those that have been approved ...
LEARN MORE
March 1, 2021
Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development
Tumor-Infiltrating Immune Cells: Explore how the identification and quantification of tumor-infiltrating lymphocytes ...
LEARN MORE
December 18, 2020
Factors to Consider When Selecting a Next Generation Sequencing (NGS) Technology
Explore the main factors you need to consider before choosing and using next generation sequencing (NGS).
LEARN MORE
December 16, 2020
Germ-Free or Antibiotic-Treated Mice? Which Model for Studying the Role of the Gut Microbiota in Preclinical Studies
Explore the differences and similarities of germ-free (GF) and antibiotic-treated mice as models for studying the role ...
LEARN MORE
December 3, 2020
The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment
Review the status of PARP inhibitors (PARPi) for prostate cancer treatment, with a focus on recent developments in drug ...
LEARN MORE
November 30, 2020
The Rising Importance of GITR Agonists as Alternative I/O Candidates for Combination Drug Strategies
Explore why glucocorticoid-induced TNFR-related protein (GITR or CD357) agonists are becoming increasingly important as alternative immunotherapy candidates for combination therapies.
LEARN MORE
November 10, 2020
SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?
Explore why upstream KRAS-mutant targets, such as SHP2 and SOS1, may lead to optimized therapeutic combinations for ...
LEARN MORE
November 6, 2020
In Vivo Imaging of Syngeneic Models for Immuno-Oncology Studies
Explore how different imaging modalities are used to monitor in vivo immuno-oncology (I/O) studies in syngeneic tumor ...
LEARN MORE
October 26, 2020
Applications and Benefits of Engineered Syngeneic Cell Lines
Explore the use and main benefits of engineered syngeneic cell lines for investigating drug targets and biological ...
LEARN MORE
October 21, 2020
Meet the CrownBio Team: Dr Marrit Putker, Organoid Research Scientist
Meet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our new Utrecht site.
LEARN MORE
October 14, 2020
Evaluating Immunotherapy Mechanism of Action with Immune Cell Lineage-Specific DTR Models
Explore how transgenic diphtheria toxin receptor (DTR) preclinical models are used to better understand immunotherapy ...
LEARN MORE
October 2, 2020
Next Generation Syngeneic Models: Top 14 Questions
Dr Davy Ouyang, CrownBio Vice President of Scientific Research & Innovation answers the most popular questions from his ...
LEARN MORE
September 22, 2020
T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug Candidates
Review the latest advances in the recall antigen assay, to provide an optimized system for screening and characterizing ...
LEARN MORE
September 17, 2020
HUB Technology: The Only Tumor Organoid Platform Available for Oncology Drug Discovery
Explore why adult stem cell (ASC)-derived HUB technology provides the only tumor organoid platform available for ...
LEARN MORE
